APEPTICO - Innovation in peptide drugs
APEPTICO - Innovation in peptide drugs
APEPTICO is an innovative biotech company that develops new peptide-based medicinal drugs for the therapeutic and prophylactic treatment of severe and chronic diseases.
Our mission is to translate structural elements of well-characterised proteins and biopharmaceuticals into pre-clinically and clinically validated peptides.
All our products address highly profitable and growing markets.
Read most recent news from APEPTICO
3rd March 2015 - APEPTICO, a privately held biotechnology company developing peptide drugs, today announced that the phase IIa clinical study of AP301-peptide delivered top-line results in the treatment of primary graft dysfunction in patients following lung transplantation.
18th February, 2015 - APEPTICO today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed the phase III clinical development strategy for APEPTICO's AP301-peptide in the orphan condition Acute Respiratory Distress Syndrome.
2nd January, 2015 - APEPTICO today announced that it has been awarded a research grand by the Wellcome Trust under the Pathfinder Award scheme to further explore the role of APEPTICO's compound ‘Enaritide' for the treatment of Pseudohypoaldosteronism type 1b (PHA type 1b).
1st December, 2014 - APEPTICO today announced that it will present major scientific break-through results for its AP301-peptide based inhalation medicine at leading international conferences in December this year.
16th July, 2014 - APEPTICO today announced that in collaboration with Dr. Rudolf Lucas, co-founder of APEPTICO and Professor of Pharmacology and Toxicology at the Vascular Biology Center, Medical College of Georgia, Georgia Regents University, has produced breakthrough results in the scientific understanding of alveolar liquid clearance regulation by the apically expressed pulmonary epithelial sodium channel (ENaC).
9th April, 2014 - APEPTICO today announced that the phase IIa clinical study of AP301 delivered top-line results in the treatment of pulmonary permeability oedema in mechanically ventilated patients suffering from Acute Respiratory Distress Syndrome.
7th February, 2014 - APEPTICO announced that it will be participating at BIO-Europe Spring (10th - 12th March, 2014, Turin, Italy). BIO-Europe Spring is the spring counterpart of BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. During BIO-Europe Spring, APEPTICO will present preliminary results of its phase IIa clinical study "Proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally-inhaled doses of AP301 on alveolar liquid clearance in acute lung injury" to the interested international pharma and biotechnology audience.
23rd October, 2013 - APEPTICO announced that it has entered into a license agreement with Chem Tech Research Incorporation (C-TRI), according to which APEPTICO will provide C-TRI with a non-exclusive license to APEPTICO's database, PEPBASE(TM). Under the terms of the Agreement, APEPTICO will receive a license fee and annual payments from C-TRI for database updates.
8th July, 2013 - APEPTICO today announced that it has received a research grant worth more than EUR 500,000 from the Austrian Research Promotion Agency (FFG) to accelerate the clinical assessment of the AP301 peptide in patients following lung transplantation.
17th April, 2013 - APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation.
31st January, 2013 - APEPTICO announced that the recent publication of an article in the journal Pulmonary Pharmacology and Therapeutics, describing the effect of APEPTICO's lead compound, AP301, in primary dog, pig and rat cells, marked the culmination of another successful year in the Company's R&D programme.
18th January, 2013 - APEPTICO today announced that its development compound AP301 has been granted orphan-drug designation by the Committee for Orphan Medicinal Products (European Medicines Agency, EC) and by the Office of Orphan Product Development (Food and Drug Administration, USA) for the clinical indication "treatment of High Altitude Pulmonary Oedema".
31st August, 2012 - APEPTICO presents clinical results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2012 Annual Congress of the European Respiratory Society.
29th June, 2012 - APEPTICO today announced the initiation of a proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance.
16th May, 2012 - APEPTICO completes a EUR 3.4 million financing round.
10th May, 2012 - APEPTICO presents early clinical development results of its inhalation therapy for prevention and treatment of oedematous respiratory failure at the 2012 International Conference of the American Thoracic Society.
26th January, 2012 - The patent "Prevention and Treatment of Hyperpermeability" invented and owned by APEPTICO ranks among the 10 most innovative inventions of the year 2011 in Austria.
25th October, 2012 - APEPTICO Announces successful completion of Phase I Trial with AP301 in Oedematous Respiratory Failure.
24th-28th September, 2011 - The Annual Congress of the European Respiratory Society (Amsterdam) has been a major success for APEPTICO's development compound AP301.
9th September, 2011 - APEPTICO today announced that it will present significant research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2011 Annual Congress of the European Respiratory Society.
27th-30th June, 2011 - APEPTICO attends the Bio International Convention in Washington DC. APEPTICO exhibits at the Austrian Pavilion #3137 in Hall A and presents latest findings of the AP301 clinical study in the Company Presentation event.
7th April, 2011 - APEPTICO today announced the initiation of a Phase I clinical trial with its lead product AP301 to assess the safety and tolerability of the orally inhaled peptide drug. AP301 is being developed for the treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation.
The 2010 Annual Conference of the European Respiratory Society was a major success for APEPTICO: Three presentations of its lead compound AP301.
Meet APEPTICO at the 2010 Annual Conference of the European Respiratory Society (September 18th - 22nd, 2010) in Barcelona and at the Bio-Europe in Munich (November 15th - 17th, 2010).
1st July, 2010 - APEPTICO's lead molecule AP301 has been validated in the porcine model of lung injury by inhalation of the peptide-aerosol.
5th August, 2010 - APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a €3 million financing round.
23rd February, 2010 - APEPTICO's lead molecule AP301 has been validated in the experimental lung transplantation model to prevent ischemia reperfusion injury.
10th February, 2010 - APEPTICO granted Orphan Drug Designation by FDA for development compound AP301.
APEPTICO will present the company and development products at the BioSquare (February 1st-2nd, 2010) and Bio-Europe Spring (March 8th-10th, 2010).
Meet APEPTICO at the Science4Life Messe in Frankfurt (October 22nd, 2009) and the Bio-Europe in Vienna (November 2nd-4th, 2009).
8th September, 2009 - APEPTICO presents its lead product AP301 at the Annual Congress of the European Respiratory Society in Vienna, Austria.
20th July, 2009 - APEPTICO granted Orphan Medicinal Product Designation by EMEA for lead product AP301.